Follow us on Twitter
twitter icon@FreshPatents


Autoimmune Diseases patents

      

This page is updated frequently with new Autoimmune Diseases-related patent applications.




new patent Ddx5 and associated non-coding rnas and modulation of th17 effector function
Methods for screening to identify agents capable of modulating ddx5 polypeptide activity are encompassed herein as are methods for using such agents to treat subjects afflicted with th17-mediated inflammatory conditions and autoimmune diseases including, without limitation, crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis, and psoriasis and methods for using such agents to treat subjects afflicted with cancer.. .

new patent Antibody polypeptides that antagonize cd40
Antibody polypeptides that specifically bind a novel epitope of human cd40 are provided. The antibody polypeptides do not exhibit cd40 agonist activity.
Domantis Limited


new patent Inhibitors of bruton's tyrosine kinase
Disclosed herein are amido compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc


new patent Benzazepine dicarboxamide compounds
Wherein r1 to r4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Disclosed herein are compounds that inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.. .
Abbvie Inc.


Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
The present invention provides a heterocyclic compound having a tlr7, tlr9, tlr7/8, tlr7/9 or tlr7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof..
Takeda Pharmaceutical Company Limited


Methods and compositions used in treating inflammatory and autoimmune diseases
Methods of treating neuroinflammation by administration of a selective protein c activator, such as recombinant human we thrombin and optionally one or more of its cofactors are disclosed. Also disclosed are pharmaceutical compositions for use in the treatment of mammals that exhibit symptoms of neurological inflammation.
The United States Government As Represented By The Department Of Veterans Affairs


Inhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc


Compositions and methods for modulating an immune response
Described herein are compositions for increasing il-12 production comprising igg or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing il-12 production comprising an agent that inhibits signaling mediated by interaction between fcrn and igg and uses of said compositions for treating autoimmune diseases.
The Brigham And Women's Hospital, Inc.


A pentacyclic triterpenoid compound with modified structure and preparation method and use thereof
The present invention relates to new pentacyclic triterpenes, their preparation method and use. The compounds of the present invention could effectively treat psoriasis and selectively inhibit in vitro differentiation of the th1 and th17 cells, thereby could be used to treat the th1- or th17-mediated autoimmune diseases..
Suzhou Botany Biomedicals Co., Ltd


Diaryl macrocycles as modulators of protein kinases

The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.. .
Tp Therapeutics, Inc.

Derivatives of polyhydroxy compounds

The present invention relates to novel compounds, e.g. For use as a medicament.
Ratiopharm Gmbh

Prognostic and diagnostic kits and herbal therapies for treating skin conditions, autoimmune diseases, inflammatory ailments and cancer

A treatment regimen for psoriasis, eczema or other skin ailment, inflammation, autoimmune disease, leukemia, melanoma or other cancer includes administering to a patient a known or discovered treatment regimen along with periodic doses of an herbal combination including sheng di huang, da huang or jin yin hua or combinations thereof.. .
Sirbal Ltd.

Prognostic and diagnostic methods and herbal therapies for treating skin conditions, autoimmune diseases, inflammatory ailments and cancer

A treatment regimen for psoriasis, eczema or other skin ailment, inflammation, autoimmune disease, leukemia, melanoma or other cancer includes administering to a patient a known or discovered treatment regimen along with periodic doses of an herbal combination including sheng di huang, da huang or jin yin hua or combinations thereof.. .
Sirbal Ltd.

Anti-krs monoclonal antibody and use thereof

The present invention relates to an anti-lysyl-trna synthetase (krs) antibody selectively binding to krs, and a use thereof and, more specifically, to an antibody binding to human krs or a fragment thereof, a method for producing the same, and a composition containing the same for diagnosing cancer, autoimmune diseases or inflammatory diseases. The antibody or fragment thereof of the present invention specifically binds to human krs, and enables krs detection and inhibition due to the absence of cross-linkage reactivity with the other proteins including the same ars family, and thus the antibody or fragment thereof can be used to detect krs and diagnose krs-related diseases, i.e., cancer, autoimmune diseases or inflammatory diseases..
Medicinal Bioconvergence Research Center

Anti-cd20 antibodies and methods of use

Compositions and methods are provided for treating diseases associated with cd20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-cd20 antibodies capable of binding to a human cd20 antigen located on the surface of a human cd20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (cdc) that is achieved by having at least one optimized cdr engineered within the variable region of the antibody.
Vaccinex, Inc.

Derivative peptide compounds and methods of use

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the polar assortant (pa) peptide, which is a scrambled peptide derived from human astrovirus protein.
Eastern Virginia Medical School

Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

Dimeric scaffold peptides comprising hiv-1 gp120 and gp41 epitopes

The present invention relates to novel peptides and methods for inducing an immune response in a subject against an antigen and for treatment, diagnosis and prognosis of infections or autoimmune diseases including infections with hcv, hiv, cmv and flu. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis..
Bionor Immuno As

Pyrrolopyrimidine compounds as kinase inhibitors

Disclosed herein are methods of using pyrrolo[2,3-d]pyrimidine btk inhibitors, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, and inflammatory diseases or conditions.. .
Pharmacyclics Llc

Histidyl-trna synthetases for treating autoimmune and inflammatory diseases

The present invention relates generally to compositions and methods comprising histidyl-trna synthetase polypeptides or other specific blocking agents for the treatment autoimmune diseases and other inflammatory diseases, including those related to jo-1 antibodies.. .
Pangu Biopharma Limited

Bispecific constructs and their use in the treatment of various diseases

The present invention relates to bispecific constructs that specifically bind to cytotoxic t cells and, simultaneously, to il5r-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including the use of the bispecific constructs in treating inflammatory and/or autoimmune diseases and cancer.. .
Numab Ag

Purinone compounds as kinase inhibitors

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc

Novel aniline derivative, pharmaceutical composition containing same, and use thereof

[solution] the present invention provides a compound represented by the general formula (i): (in the formula, r1, r2 and r3 are each a hydrogen atom, a halogen atom, a c1-6 alkyl group, a halo c1-6 alkyl group or the like, r4 is a c1-6 alkyl group or the like, r5 is a c1-6 alkyl group or the like, r6 is a c1-6 alkyl group or the like, r7 is a hydrogen atom, a halogen atom, a c1-6 alkyl group or the like, r8 is a halogen atom, a c1-6 alkyl group, a halo c1-6 alkyl group, a c1-6 alkoxy group or the like, and r9 is a hydrogen atom or a c1-6 alkyl group.) or a pharmaceutically acceptable salt thereof, a pharmaceutical compositions containing same, and use thereof. The compounds of the present invention have an excellent s1p1 receptor antagonistic activity and therefore are useful as an agent for the treatment or prevention of autoimmune diseases and the like..

Immunomodulatory compositions

The present invention relates to pharmaceutical compositions comprising mesenchymal cells (mscs) and additional agents for blocking co-stimulation of the immune system. The compositions may optionally further comprise a therapeutic cell, a therapeutic tissue, and/or a therapeutic organ implant.
Isletone Ab

Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use

Prodrugs of ibrutinib, pharmaceutical compositions comprising the prodrugs, and methods of using the prodrugs and pharmaceutical compositions for treating autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions are disclosed.. .

Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases

The described invention relates to methods for preventing or treating graft-versus-host disease while preserving a graft-versus-tumor effect, increasing survival of, preserving alloreactivity, or a combination thereof in a patient with a tumor receiving a transplant. The described methods comprise administering to the patient a therapeutic amount of a pharmaceutical composition comprising a rho kinase inhibitor compound, e.g., telmisartan or related angiotensin receptor blockers, and a pharmaceutically acceptable excipient.
Hackensack University Medical Center

Nanoparticle-mediated delivery of cytokines for maintenance of the regulatory t cell phenotype

Compositions for delivery of growth factors needed for stable tregs and methods of use thereof are provided. In preferred embodiments, the compositions can induce, increase, or enhance a functionally robust induced cd4 treg population (e.g., foxp3+ treg) in vivo or ex vivo.
Yale University

Immunoglobulin constant region fc receptor binding agents

Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function.
Gliknik Inc.

Novel synthetic biology-based adcc technology

A novel synthetic biology-based adcc technology is provided that enhances or enables adcc response. The novel adcc technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable..
1globe Biomedical Co., Ltd.

Inhibitors of bruton's tyrosine kinase

Disclosed herein are reversible and irreversible inhibitors of bruton's tyrosine kinase (btk). Also disclosed are pharmaceutical compositions that include the compounds.
Pharmacyclics Llc

Fluorometric immunoassay for detection of anti-dsdna antibodies

The present invention relates to the field of immunological methods, more precisely to the field of detection methods for antibodies against double-stranded dna (dsdna) for diagnostics of chronic autoimmune diseases, such as systemic lupus erythematosus (sle). The fluorometric immunoassay method for detection of anti-dsdna solves the technical problem of designing a method for detection of the aforesaid antibodies, which would be faster, cheaper and less toxic as the standard farr-ria method, but would have the same diagnostic specificity (which is 100%) and improved diagnostic sensitivity (for 3%).
Univerzitetni Klinicni Center Ljubljana

Tlr3 binding agents

The present invention relates to antibodies (e.g. Monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind tlr3, and that optionally further modulate, e.g.
Innate Pharma

Compositions and methods of use for therapeutic antibodies

The present invention relates to antibodies that specifically bind to the baff receptor (baffr). The invention more specifically relates to specific antibodies that are baffr antagonists with in vivo b cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting b cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas..
Novartis Ag

Method of inhibiting metastasis of cancer cells and modulating autoimmune diseases using gal-3bp-fc fusion protein

A tgal-3bp-fc fusion protein, a pharmaceutical composition, an isolated nucleic acid, a recombinant expression vector, and a method of inhibiting, decreasing, reducing, suppressing or limiting metastasis of cancer cells, and immunosuppressing or modulating phagocytosis and t-cell functions by using the same are disclosed herein. The tgal-3bp-fc fusion protein comprises: a truncated gal-3 binding protein with domain 4, and at least an fc fragment of an immunoglobulin g.
Show-chwan Memorial Hospital

Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as peg400 but essentially free of organic solvents and non-solubilized particles.

Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor

Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
Janssen Pharmaceutica Nv

S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by pde7

The present invention relates to a family of s-substituted quinazoline derivatives that inhibitors of the enzyme phosphodiesterase 7 (pde7), useful for the treatment or prevention of diseases mediated by said enzyme, especially inflammatory, neurodegenerative, neurological, psychiatric and/or autoimmune diseases.. .
Consejo Superior De Lnvestigaciones Cientificas (csic)

Antigen-specific immunotherapy using tolerizing liposomes

The invention relates to a pharmaceutical composition for the treatment of allergic and autoimmune diseases by in vivo generation of tolerogenic dendritic cells (dcs) and macrophages using tolerizing liposomes loaded with at least one maturation inhibitor of dcs and at least one antigen or allergen or peptide derived thereof, made of at least one preparation, and comprising a matrix suitable for locally restricted sustained release of therapeutically effective doses of therapeutics including tolerogenic liposomes tailored for effective phagocytosis, at least one immune modulator of phagocytosis, and optionally at least one immune modulator suitable for enhancing the suppressive function of regulatory t cells and/or inhibiting the production of pro-inflammatory cytokines, and/or inhibiting the biological activity of secreted pro-inflammatory cytokines at the site of antigen or allergen presentation.. .
Pls-design Gmbh

Liposome-based immunotherapy

The present invention provides a liposome encapsulating an autoantigen, wherein the liposome has a size comprised from 500 to 15000 nm and the liposome membrane comprises phosphatydilserine (ps) in an amount comprised from 10 to 40% by weight with respect to the total membrane liposomal composition. Pharmaceutical or veterinary compositions comprising a therapeutically effective amount of said liposome are also provided.
InstituciÓ Catalana De Recerca I Estudis AvanÇats

Nucleic acid capable of inhibiting expression of beta-2gpi

The present invention provides a nucleic acid having activity to suppress expression of β2gpi, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as aps, sle and the like and thrombosis in hemodialysis.. .
Kyowa Hakko Kirin Co., Ltd.

Baff selective binding compounds and related methods

The present invention relates to peptide antagonists that bind with high specificity and affinity to b-lymphocyte stimulator (“baff”), thereby antagonizing baff receptor (“baff-r”) signaling. The invention more specifically relates to vnar single chain antibodies derived from nurse shark that bind to baff, baff antagonist compounds and compositions comprising a baff specific vnar binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo b cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete b cells, such as in autoimmune diseases including systemic lupus erythematosus (sle), rheumatoid arthritis (ra) or multiple sclerosis (ms), and in certain hematological cancers, including lymphomas, leukemias and myelomas..
Ossianix, Inc.

Heterocyclic compounds and their uses

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.

Tnfa-il-17 bispecific antibodies

Bispecific tetravalent antibodies against il-17 and tnfa, useful in therapy, e.g. The treatment of rheumatoid arthritis and other autoimmune diseases and/or to reduce pathological inflammatory conditions..
Hoffmann-la Roche Inc.

Derivatives of tartaric acid

The present invention relates to novel compounds, e.g. For use as a medicament.
Ratiopharm Gmbh

Use of cd83 in combination therapies

The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of cd83. In some embodiments, cd83 is coadministered to a subject with at least one other immunosuppressive compound.
Argos Therapeutics, Inc.

Supplement for improving immunotolerance, intestinal environment and intestinal tract barrier

A supplement for improving immunotolerance, intestinal environment and intestinal tract barrier for the purpose of improving intestinal vulnerability, food intolerance or allergy, systemic allergy, autoimmune diseases and systemic inflammatory diseases by immune reactions which is obtained by mixing an ingredient (a) comprising at least one of a probiotic that is any one of lactic acid bacteria, lactobacillus bifidus, saccharified bacteria, natto bacteria and yeast fungus, or a mixture thereof, a biogenic that is a bacteria-producing substance such as lactic acid bacteria, and a prebiotic is indigestible food ingredients such as oligosaccharide, dietary fiber, substance stimulating production of lactobacillus bifidus, and others or a mixture thereof and an ingredient (b) comprising at least one of l-glutamine, zinc, vitamin a and vitamin d.. .

Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases

Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of btk, mtor kinase, and bcl-2 or their signaling pathways, and immunomodulatory drugs.
Zhejiang Dtrm Biopharma Co. Ltd.

Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles

And pharmaceutically acceptable derivatives thereof. Methods of treatment of neoplastic and autoimmune diseases with these compounds are also disclosed..

Anti-cd19 antibodies

The present invention provides humanized, chimeric and human anti-cd19 antibodies, anti-cd19 antibody fusion proteins, and fragments thereof that bind to a human b cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various b-cell disorders, including b-cell malignancies and autoimmune diseases.
Immunomedics, Inc.

Particles containing phospholipids or bioactive fatty acids and uses thereof

The subject matter disclosed herein is directed to particles containing phospholipids and/or fatty acids and the uses thereof for treating autoimmune diseases, inflammatory diseases and for modulating immune and inflammatory responses. Methods of preparing the particles are also described..
The University Of North Carolina At Chapel Hill

Substituted anilines as ccr(4) antagonists

Aniline compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
Chemocentryx, Inc.

Halofuginone analogs for inhibition of trna synthetases and uses thereof

The present invention provides novel analogs and derivatives of halofuginone. The invention also provides pharmaceutical and cosmetic compositions thereof and methods for using halofuginone analogs in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, ischemic damage, transplant and implant rejection, neurodegenerative diseases, and cosmetic applications..
Children's Medical Center Corporation



Autoimmune Diseases topics:
  • Immune Diseases
  • Autoimmune Disease
  • Autoimmune Diseases
  • Immune Disease
  • Autoimmune
  • Rheumatoid Arthritis
  • Antibodies
  • Proliferative
  • Nucleotide
  • Antagonist
  • Infectious Diseases
  • Inflammatory Disease
  • Infectious Disease
  • Infectious
  • Multiple Sclerosis


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Autoimmune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.3606

    file did exist - 2912

    0 - 1 - 53